Nine mania cases emerge after starting keto for mental illness

Nine people developed hypomania or mania within two months of starting a ketogenic diet, a signal that now sits squarely in the middle of the growing keto conversation around mental illness.

Christopher M. Palmer, MD, of Harvard Medical School and McLean Hospital in Belmont, Massachusetts, reported the case series in Frontiers in Nutrition. Eight participants developed hypomania and one developed mania. Seven of the nine had no prior history of a bipolar-spectrum disorder, which makes the timing especially important for people who begin keto with depression, bipolar disorder, schizophrenia or other serious psychiatric conditions in mind.

The paper does not suggest that keto is broadly dangerous, but it does sharpen the line between keto for weight loss and therapeutic keto under medical supervision. Palmer has been one of the most visible advocates for metabolic psychiatry, where ketogenic diets are used as a treatment strategy rather than a casual nutrition trend. That distinction matters because many people try keto on their own, outside specialty care, and may not realize that a burst of energy is not always a benign sign of “adaptation.”

The case series offers one important reassurance: none of the nine required hospitalization or the addition of mood-stabilizing medications. Even so, the message for keto-curious readers with mood disorders is to watch the earliest warning signs closely. A sharp drop in sleep, unusually high energy, racing thoughts, pressured or unusually rapid speech, agitation, irritability, impulsive spending, risky behavior or a sudden sense of invincibility in the first days to eight weeks after starting keto should be treated as a stop signal. The diet should be paused and a clinician contacted promptly, especially if symptoms are escalating rather than settling.

That caution lands in a field that is still very active. Stanford Medicine has highlighted a four-month pilot trial led by Shebani Sethi, MD, involving 21 adults with schizophrenia or bipolar disorder who were already taking antipsychotic medication and also had metabolic abnormalities. Participants were instructed to follow a ketogenic diet built around roughly 10% of calories from carbohydrates, 30% from protein and 60% from fat. Separately, the International Ketogenic Diet Study Group has long described ketogenic dietary therapies as established, effective nonpharmacologic treatment for intractable childhood epilepsy.

The new case series does not close the door on therapeutic keto. It does, however, give clinicians and patients a sharper checklist before the first egg, avocado and electrolyte drink ever hit the plate.